Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 14Thoracic 3Head & Neck 3Gynecologic 3Gastrointestinal 3CNS 3Genitourinary 2Breast 2Sarcoma 1NET 1Dermatologic 1

Conditions

Melanoma 284Lymphoma, T-Cell, Cutaneous 108Mycosis Fungoides 83Sezary Syndrome 80Lymphoma, Non-Hodgkin 74Leukemia, Lymphocytic, Chronic, B-Cell 74Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Burkitt Lymphoma 68Lymphoma, Mantle-Cell 67Lymphoma, B-Cell, Marginal Zone 67Hodgkin Disease 67Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 65Lymphoma, Large-Cell, Immunoblastic 65Lymphoma, Large-Cell, Anaplastic 62Lymphoma 58Immunoblastic Lymphadenopathy 56Intraocular Lymphoma 43Breast Neoplasms 41Skin Neoplasms 40Neoplasms 37Carcinoma, Renal Cell 35Waldenstrom Macroglobulinemia 33Neoplasm Metastasis 33Uveal Melanoma 29Leukemia, Myeloid, Acute 23Leukemia, Hairy Cell 23Carcinoma, Non-Small-Cell Lung 22Sarcoma 21

Interventions

cixutumumab 1Salts 1Octreotide 1Everolimus 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Insulinoma × Dermatologic × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡